These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19954718)

  • 1. Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels.
    Eriguchi R; Umakoshi J; Miura S; Sato Y
    Clin Nephrol; 2009 Dec; 72(6):423-9. PubMed ID: 19954718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Moriishi M; Kawanishi H; Fukagawa M
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():62-6. PubMed ID: 21595855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
    Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
    Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
    Gorai I; Hattori S; Tanaka Y; Iwaoki Y
    J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5.
    Haghverdi F; Farbodara T; Mortaji S; Soltani P; Saidi N
    Iran J Kidney Dis; 2014 Nov; 8(6):461-6. PubMed ID: 25362221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
    Ma HY; Chen S; Lu LL; Gong W; Zhang AH
    Horm Metab Res; 2021 Nov; 53(11):730-737. PubMed ID: 34740274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy.
    Cosman F; Nieves JW; Zion M; Barbuto N; Lindsay R
    Osteoporos Int; 2008 Apr; 19(4):529-35. PubMed ID: 17929072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Endocr J; 2008 Mar; 55(1):41-8. PubMed ID: 18187874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
    Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
    Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life.
    Sugiya N; Nakashima A; Takasugi N; Kawai A; Kiribayashi K; Tanaka J; Kohno N; Yorioka N
    Osteoporos Int; 2011 May; 22(5):1573-9. PubMed ID: 20652228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX; Li H
    Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of raloxifene treatment in postmenopausal women with CKD.
    Ishani A; Blackwell T; Jamal SA; Cummings SR; Ensrud KE;
    J Am Soc Nephrol; 2008 Jul; 19(7):1430-8. PubMed ID: 18400939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
    Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial.
    Uusi-Rasi K; Beck TJ; Semanick LM; Daphtary MM; Crans GG; Desaiah D; Harper KD
    Osteoporos Int; 2006; 17(4):575-86. PubMed ID: 16392026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
    J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density and parathyroid function in patients on maintenance hemodialysis.
    Ambrus C; Almasi C; Berta K; Deak G; Marton A; Molnar MZ; Nemeth Z; Horvath C; Lakatos P; Szathmari M; Mucsi I
    Int Urol Nephrol; 2011 Mar; 43(1):191-201. PubMed ID: 20091221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.